Publications by authors named "Juan Schropp"
Homocysteine is an independent risk factor for cardiovascular disease in the general population. In addition, it plays a main role in the development of atherogenesis and thrombosis, particularly in end-stage renal disease patients. Therefore, hemodialysis patients are under the burden of homocysteine toxic effects, present in nearly 90% of dialysis patients.
View Article and Find Full Text PDFArticle Synopsis
- Hemodialysis access grafts commonly experience thrombosis, a serious complication, which clopidogrel (a platelet aggregator inhibitor) was tested to prevent.
- In a study of 24 chronic hemodialysis patients, one group received no antithrombotic therapy while the other group was given clopidogrel post-surgery, with results showing significant differences in thrombotic events between the groups.
- The group on clopidogrel had notably fewer thrombosis incidents, longer access patency, spent more time on dialysis, and exhibited better survival rates, suggesting clopidogrel's effectiveness in improving patient outcomes.
Homocysteine is a risk factor for cardiovascular disease. Mutations in a key enzyme in homocysteine metabolism, methylenetetrahydrofolate reductase, may contribute to hyperhomocysteinemia and alter folate and cobalamin levels. After starting hemodialysis, 10 mg oral folate daily and 500 micrograms intravenous methylcobalamin once weekly were prescribed to 27 hemodialysis patients (time on hemodialysis > or = 12 months) and two groups were defined: Group A normal; Group B heterozygous.
View Article and Find Full Text PDF